Q-omics provides the consensus-scored PDE12 profile across patient tissues and cancer cell-line models. PDE12 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, PDE12 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PDE12 RNA expression shows 19,963 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SCLC, KIRC, and UVM as cancer lineages where PDE12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE12 survival associations across molecular data types. PDE12 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE12 RNA expression–survival associations across cancer types. High PDE12 expression shows unfavorable associations in CESC and LIHC, but favorable associations in SCLC, KIRC, READ and COAD. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for PDE12 RNA expression.
This table summarizes PDE12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDE12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE12 shows lower tumor expression in KIRC, THCA and LUSC and higher tumor expression in LIHC, COAD and STAD. The KIRC box plot shows higher PDE12 RNA expression in normal versus tumor tissue (log2 FC = −0.773, t-test p < 0.001).
This table shows molecular features associated with PDE12 in patient tissues and cancer cell lines. In patient samples, PDE12 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
